Study Suggests New Stool-Based Syndecan-2 Methylation Test Improves Detection Of CRC, ACN

GI & Hepatology News (8/13, Pass) reports, “A new stool-based syndecan-2 methylation (mSDC2) test may improve the detection of colorectal cancer (CRC) and advanced colorectal neoplasia (ACN), based on a prospective, real-world study.” According to researchers, the study’s “findings suggest that the mSDC2 assay could improve the efficacy and resource utilization of existing screening programs.” The findings were published in Gastroenterology.